NCT03806153 (EMCIMO) is a NA clinical trial of Morphokinetic in Reproductive Disorder, sponsored by University Hospital, Rouen.

Who is sponsoring NCT03806153?

NCT03806153 is sponsored by University Hospital, Rouen.

What drugs are being tested in NCT03806153?

Interventions in NCT03806153: Morphokinetic.

What condition does NCT03806153 study?

NCT03806153 studies Reproductive Disorder.

Is NCT03806153 still recruiting?

NCT03806153 is currently recruiting now. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT03806153: EMCIMO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interest of Morphokinetic Parameters of Early Embryonic Development in the Birth Rates in Vitro Fertilization

Recruiting now NA Last updated 20 February 2026

What this trial tests

NA trial testing Morphokinetic in Reproductive Disorder in 520 participants. Currently enrolling.

Timeline

26 October 2020

Primary endpoint
1 March 2026

1 March 2026

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	520
Start date	26 October 2020
Primary completion	1 March 2026
Estimated completion	1 March 2026
Sites	2 locations across France

Drugs / interventions tested

Morphokinetic

Conditions studied

Reproductive Disorder — all drugs for Reproductive Disorder →

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 59, any sex, with Reproductive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In France, nearly 3% of children are conceived by the technique of Assisted Reproductive Medicine, of which nearly 70% by in vitro fertilization (IVF). The rates of clinical pregnancy by oocyte retrieval or embryo transfer have not changed much. The use of mono-embryo transfer reduces the risk of multiple pregnancies and associated obstetric complications. The choice of embryo to transfer or freeze is a key element in improving the chances of success of IVF. It is usually based on conventional morphological criteria (reference method) that are punctual, qualitative and subjective. However, embryo morphology at early stages has little predictive value for obtaining a late-stage embryo and its chances of implantation. The recent use of time-lapse technology during embryonic culture makes it possible to associate morphological criteria with continuous monitoring of the kinetics of embryonic development. The choice of the embryo to be transferred is then made according to morphokinetic criteria (conventional morphological criteria to which are added the data of the kinetics of embryonic development). Two recent retrospective studies give contradictory results, the first shows higher birth rates in the group of embryos selected according to conventional morphological criteria, the second concludes that morphokinetic analysis is superior. Morphokinetic criteria would also be more objective and reproducible. However, the use of morphokinetic parameters remains controversial in the literature.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Rouen trials

Trials by the same sponsor.

NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03806153 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03806153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing